ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 0002

Age-Related Antigen Discovery in Giant Cell Arteritis

Haleigh Miller1, Y. Rose Citron2, Peter Grayson3, Rennie Rhee4, David Cuthbertson5, Nader A. Khalidi6, Curry L. Koening7, Carol A. Langford8, Carol A. McAlear9, Paul A. Monach10, Larry Moreland11, Christian Pagnoux12, Philip Seo13, Peter Merkel14, Sharon Chung1 and Joseph DeRisi2

Affiliations: 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 4University of Pennsylvania, Philadelphia, PA, 5Health Informatics Institute, University of South Florida, Tampa, 6Department of Medicine, McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada, 7University of Texas Dell Medical School, Austin, TX, 8Cleveland Clinic, Moreland Hills, OH, 9University of Pennsylvania, Philadelphia, Philadelphia, 10VA Boston Healthcare System, Boston, MA, 11University of Colorado, Denver, CO, 12Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 13Johns Hopkins University, Baltimore, MD, 14Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Aging, Autoantibody(ies), giant cell arteritis, Vasculitis

Session Information

Date: Sunday, November 8, 2026

Title: (0001-0008) Vasculitis - Basic and Translational Science Poster A

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The striking restriction of GCA to individuals over 50 years old suggests that age-related molecular changes may drive the pathogenesis of this disease. The specific age-related mechanisms triggering this large-vessel vasculitis remain unknown, limiting diagnostic and therapeutic approaches. Previous work investigating temporal artery biopsies revealed extensive antibody deposition in diseased tissue, suggesting autoantibody responses to unknown vascular antigens may play a role in disease pathogenesis.

Methods: To identify novel autoantibodies in patients with systemic vasculitis, a phage immunoprecipitation sequencing (PhIP-Seq) study was conducted among 956 patients with 6 different types of vasculitis and compared the results to over 60,000 samples from individuals without vasculitis. PhIP-seq is an unbiased approach to identify autoantibody targets across the entire human proteome. This method utilizes a library of 49-amino-acid peptides that covers the human genome cloned into T7 phage that are immunoprecipitated with patient antibodies and analyzed via next-generation sequencing (Fig 1).

Results: In 235 patients with GCA, PhIP-seq revealed autoantibodies targeting the amyloid-forming cleavage product of MFGE8, known as medin, in 12 (5.1%) of patients and 0% of patients without vasculitis (Fig 2). Anti-medin autoantibodies were absent in other types of vasculitis except for 1/183 (0.5%) patients with Takayasu arteritis. PhIP-seq in an orthogonal validation cohort confirmed GCA-specific autoreactivity to medin peptides. Medin is the most common human amyloid, found in the medial layer of large arteries of nearly all individuals over 50 years old. Medin amyloid has been shown to be phagocytosed by giant cells in GCA and its parent protein, MFGE8, has been associated with GCA in genome-wide association studies. Additional exploration into conformational antibody responses with recombinant expression and fibril formation of medin, followed by immunogold labeling with patient sera and TEM visualization, demonstrated autoantibodies targeting medin amyloid fibrils in patients with GCA.

Conclusion: Unbiased, proteome-wide PhIP-seq identified autoantibodies to medin in patients with GCA, connecting age-related amyloid accumulation to disease pathogenesis and implicating medin as a candidate autoimmune antigen. Despite the relatively low seroprevalence by this assay, these antibodies may be clinically significant due to their high specificity for GCA and the potential links between medin and GCA disease pathogenesis.

Supporting image 1The human proteome phage display library is designed to represent all proteins in the human body, including all isoform variants, in a tiled design of 49 amino acid peptides with 24 amino acid overlaps. The phage library is incubated with patient serum and antibodies that bind peptides on phage are immunoprecipitated (IP) and amplified in E. coli. After 3 rounds of incubation, IP, and enrichment, the amplified phage are sequenced to identify immunogenic peptides.

Supporting image 2GCA patient serum binds to peptides corresponding to the medin peptide sequence in PhIP-seq. Other forms of vasculitis and healthy controls (HC) do not demonstrate medin-specific enrichment. Medin peptides present in samples were normalized to reads per 100,000 (RPK), averaged and log-transformed.


Disclosures: H. Miller: None; Y. Citron: None; P. Grayson: None; R. Rhee: Novartis, 12,; D. Cuthbertson: None; N. Khalidi: AbbVie, 12,, 12, , Bristol Myers Squibb, 12,, 12, , Fresnius Kabi, 12,, GSK, 12,, Mallinckrodt Pharmaceuticals, 12,, Otsuka Pharmaceuticals, 12,, Pfizer, 12,, Roche, 12,, Sanofi, 12,, 12, ; C. Koening: Amgen, 12,; C. Langford: AstraZeneca, 12,, Bristol-Myers Squibb(BMS), 12,, GlaxoSmithKlein(GSK), 12,, NS Pharma, 12,; C. McAlear: None; P. Monach: Boehringer-Ingelheim, 12,; L. Moreland: None; C. Pagnoux: Amgen, 12,, AstraZeneca, 12,, CSL Vifor, 12,, NS Pharma, 12,, Otsuka, 12,; P. Seo: None; P. Merkel: AbbVie, 12,, 12, , Alexion, 12,, Amgen, 12,, 12, , Argenx, 12,, AstraZeneca, 12,, 12, , Boehringer Ingelheim, 12,, 12, , Bristol Myers Squibb, 12,, 12, , Capstan Therapeutics, 12,, Electra, 12,, 12, , Eli Lilly, 12,, GSK, 12,, 12, , Kyverna, 12,, Lifordi, 12,, 12, , Melodia Therapeutics, 12,, Neutrolis, 12,, 12, , Novartis, 12,, NS Pharma, 12,, Otsuka, 12,, Q32 Bio, 12,, 12, , 12, , Quell, 12,, Sanofi, 12,, Serpass, 12,, Sparrow, 12,, 12, , Takeda, 12,, 12, , UpToDate, 12,; S. Chung: None; J. DeRisi: Delve Bio, 12,, PHC Global, inc., 12,.

To cite this abstract in AMA style:

Miller H, Citron Y, Grayson P, Rhee R, Cuthbertson D, Khalidi N, Koening C, Langford C, McAlear C, Monach P, Moreland L, Pagnoux C, Seo P, Merkel P, Chung S, DeRisi J. Age-Related Antigen Discovery in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/age-related-antigen-discovery-in-giant-cell-arteritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/age-related-antigen-discovery-in-giant-cell-arteritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology